ArticlePharmacoEconomics - open2024

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.

Andrea Favre-Bulle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.